Fast Acting Joint Health Composition and Use Thereof
A joint health composition is disclosed that, when administered to mammals in a therapeutically effective amount, can reduce inflammation and joint pain. The joint health composition contains a collagen, and at least one anti-inflammatory adjuvant in the delivery form of lipid multiparticulates. The joint health composition show increased bioavailability and a reduction in inflammation and joint pain in a reduced time period.
1 . A joint health composition for improving one or more of joint health and inflammation, comprising
a lipid multiparticulate comprising at least one anti-inflammatory adjuvant and a lipid matrix, wherein the anti-inflammatory adjuvant is dispersed within the lipid matrix, and
collagen;
wherein the anti-inflammatory adjuvant comprises an extract or isolate from a natural source that inhibits one or more of: interleukin-1 expression, interleukin-6 expression, NF-KB expression, cyclooxygenase-2 (COX-2) expression, inducible nitric oxide synthase (iNOS) expression, 5-lipoxygenase biosynthesis, and tumor necrosis factor-α (TNF-α) expression.
2 . The composition according to claim 1 , wherein the anti-inflammatory adjuvant is encapsulated by the lipid matrix.
3 . The composition according to claim 1 , wherein the anti-inflammatory adjuvant is present in the lipid multiparticulate in an amount from about 1% to about 80% by weight based on a total weight of the lipid multiparticulate particles.
4 . The composition as defined in claim 1 , wherein the joint-health composition is in a form of a capsule, a tablet, a powder, or is suspended in a liquid.
5 . The composition as defined in claim 1 , wherein collagen is contained in the joint health composition in an amount greater than about 50 mg up to about 200 mg or less.
6 . The composition as defined in claim 1 , wherein the anti-inflammatory adjuvant is contained in the joint health composition in an amount from about 2.5 mg to about 200 mg.
7 . The composition as defined in claim 1 , wherein the collagen comprises undenatured Type II collagen or native type II collagen.
8 . The composition as defined in claim 1 , wherein the anti-inflammatory adjuvant comprises an extract and/or isolate obtained from Andrographis paniculate, Tamarind seed, Boswellia serrata, green lipped mussel ( Perna canaliculus ), turmeric ( Curcuma longa ), stinging nettle ( Urtica dioica ), Cat's claw ( Uncaria tomentosa ), or bromelain.
9 . The composition as defined in claim 1 , wherein the anti-inflammatory adjuvant is a boswellic acid, tamarind seed extract, an andrographolide, or combinations thereof.
10 . The composition as defined in claim 1 , wherein the anti-inflammatory adjuvant is
(a) an andrographolide, and wherein the andrographolide is contained in the joint health composition in an amount from about 2.5 mg to about 200 mg,
(b) a tamarind seed extract, and wherein the tamarind seed extract is contained in the joint health composition in an amount from about 10 mg to about 200 mg, or
(c) a boswellic acid, wherein the boswellic acid comprises 11-keto-β-boswellic acid, acetyl-11-keto-β-boswellic acid, or a combination thereof, and wherein the boswellic acid is contained in the joint health composition in an amount from about 10 mg to about 200 mg.
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . A method of improving one or more of joint pain and inflammation in a mammal, comprising:
supplying to the mammal a therapeutically effective amount of a joint-health composition comprising collagen and at least one anti-inflammatory adjuvant, wherein the at least one anti-inflammatory adjuvant is in the form of a lipid multiparticulate; and
wherein the anti-inflammatory adjuvant comprises an extract or isolate from a natural source that inhibits one or more of: interleukin-1 expression, interleukin-6 expression, NF-kB expression, cyclooxygenase-2 (COX-2) expression, inducible nitric oxide synthase (iNOS) expression, 5-lipoxygenase biosynthesis, and tumor necrosis factor-α (TNF-α) expression.
15 . The method as defined in claim 14 , wherein the improvement in one or more of joint pain and inflammation is evidenced by a 10% or greater decrease in serum interleukin-1, interleukin-6, TNF-α, COX-2, SOX-9, MMP-13, or a combination thereof, or a subjective reduction in one or more of joint pain and inflammation, in about two weeks or less.
16 . The method as defined in claim 14 wherein the therapeutically effective amount of the joint health composition administered to the mammal includes a collagen amount of at least 0.3 mg/kg of body weight per day to about 3 mg/kg of body weight per day.
17 . The method as defined in claim 14 , wherein the collagen comprises undenatured Type II collagen or native type II collagen.
18 . The method as defined in claim 14 , wherein the anti-inflammatory adjuvant comprises an extract and/or isolate obtained from Andrographis paniculate, Tamarind seed, Boswellia serrata, green lipped mussel ( Perna canaliculus ), turmeric ( Curcuma longa ), stinging nettle ( Urtica dioica ), Cat's claw ( Uncaria tomentosa ), or bromelain.
19 . The method as defined in claim 14 , wherein the anti-inflammatory adjuvant is a boswellic acid tamarind seed extract (TSE), an andrographolide, or combinations or derivatives thereof.
20 . The method as defined in claim 14 , wherein the improvement in one or more of joint pain and inflammation is evidenced in about one week or less.
21 . The method as defined in claim 14 , wherein the improvement in one or more of joint pain and inflammation is evidenced by a decrease in serum: interleukin-1, interleukin-6, TNF-α, COX-2, SOX-9, MMP-13, or a combination thereof of at least about 15%, after 10 days or less.
22 . The method as defined in claim 14 , wherein improvement in one or more of joint pain and inflammation is evidenced by a decrease in
(a) interleukin-1 serum of at least about 20%,
(b) interleukin-6 serum of at least about 20%, or
(c) matrix metallopeptidase 13 serum of at least about 20%.
23 . (canceled)
24 . (canceled)
25 . The method as defined in claim 14 , wherein the joint health composition is administered to the mammal in a therapeutically effective amount sufficient to change a Kellgren-Lawrence score of the mammal by at least about 20%.
26 . The method as defined in claim 14 , wherein the joint health composition administered daily.
27 . A joint health composition for improving one or more of joint health and inflammation, comprising
an extract and/or isolate obtained from Andrographis paniculate, Tamarind seed, green lipped mussel ( Perna canaliculus ), turmeric ( Curcuma longa ), stinging nettle ( Urtica dioica ), Cat's claw ( Uncaria tomentosa ), and bromelain; and
collagen.
28 . The joint health composition as defined in claim 27 , wherein the extract and/or isolate is from Andrographis paniculate; or Tamarind seed, and the collagen is undenatured Type II collagen.